CMPS is the cleanest single-name read-through from the psychedelics EO
The Opportunity
This is a LONG on Compass Pathways (CMPS) because it is a named, tradeable developer sitting closest to the “policy prioritisation” narrative that investors can translate into probability-weighted timeline compression. The mechanism sign is positive (supplier beneficiary) with medium role-resolution confidence: the market doesn’t need statutory change to re-rate a small-cap biotech if it believes FDA engagement cadence and prioritisation improves. The edge is still contained (no Tier-1 at discovery), but the narrative is heating up fast.
The Timing
The macro tape is Mixed 58 with high crosswind risk (66), and the wind context is neutral (Neutral 8). That implies this is not a “set and forget” fundamental re-rate; it is a policy-implementation trade where reversals are plausible if guidance disappoints. Freshness is 65 and the oldest claim date detected is 18 April 2026, consistent with a recent catalyst. The convert-to-higher-confidence trigger is any FDA/HHS operational memo that turns prioritisation language into steps with dates; the invalidate trigger is an explicit narrowing that excludes CMPS programs from any accelerated pathway.
The Evidence
The primary-policy boundary document is the same EO: whitehouse.gov . Incremental coverage beyond that is mostly issuer-led comms rather than independent operational detail, which is why trade confidence sits at 55 despite a 60 conviction score. The price context is straightforward: CMPS closed at $9.25 (-2.2%), which is consistent with two-way churn rather than “policy certainty.”